不同剂量米非司酮治疗子宫肌瘤的临床效果观察

Observation on the clinical effects of different doses of mifepristone in treatment of uterine myoma

目的探讨不同剂量的米非司酮治疗子宫肌瘤的临床效果对比。方法就该院在2014年1月-2015年12月收治的子宫肌瘤患者中,选择具有可比性的110例患者作为研究对象,将其随机分成观察组与对照组,每组55例,观察组给予患者12.5 mg/d剂量的米非司酮治疗,对照组给予患者25 mg/d剂量的米非司酮治疗,分别对比两组患者治疗后的各项激素水平、子宫肌瘤体积缩小情况、痛经改善率以及不良反应。结果两组患者治疗后的各项激素水平差异不明显,两组患者的子宫肌瘤体积在治疗后都有明显的缩小,观察组患者的痛经改善率明显低于对照组患者的痛经改善率,观察组患者的不良反应发生率明显少于对照组患者的不良反应发生率,P<0.05为差异具有统计学意义。结论小剂量的米非司酮治疗子宫肌瘤临床疗效确切,且不良反应发生率更低,安全性更高,值得临床的推广及应用。

Objective To compare the clinical effects of different doses of mifepristone in treatment of uterine myoma. Methods A total of 110 uterine myoma patients were selected from the hospital from January 2014 to December 2015, then they were randomly divided into observation group and control group, 55 patients in each group. The patients in observation group were treated by mifepristone （ 12.5 mg/d）, while the patients in control group were treated by mifepristone （25 mg/d） . The levels of hormones, reduction of uterine volume, improvement rates of dysmenorrilea, and adverse reactions after treatment in the two groups were compared. Results After treatment, there was no statistically significant difference in hormones levels between the two groups, uterine myoma volumes in the two groups af- ter treatment decreased significantly. The improvement rate of dysmenorrhea and incidence rate of adverse reactions in observation group were statistically significantly lower than those in control group （P〈0. 05） . Conclusion The clinical efficacy of low-dose mifepristone in treatment of uterine myoma is significant with lower incidence rate of adverse reactions and higher security, which is worthy of clinical population and application.